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BALB/c Mice resist infection with Bartonella bacilliformis
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Abstract
Background: Bartonellosis due to Bartonella bacilliformis is a highly lethal endemic and sometimes
epidemic infectious disease in South America, and a serious public health concern in Perú. There is
limited information on the immunologic response to B. bacilliformis infection. The objective of this
research was to produce experimental infection of BALB/c mice to B. bacilliformis inoculation.
Findings: BALB/c mice were inoculated with 1.5, 3.0 or 4.5 × 108 live B. bacilliformis using different
routes: intraperitoneal, intradermal, intranasal, and subcutaneous. Cultures of spleen, liver, and
lymph nodes from one to 145 days yielded no cultivable organisms. No organs showed lesions at
any time. Previously inoculated mice showed no changes in the reinoculation site.
Conclusion: Parenteral inoculation of live B. bacilliformis via different infection routes produced no
macroscopic or microscopic organ lesions in BALB/c mice. It was not possible to isolate B.
bacilliformis using Columbia blood agar from 1 to 15 days after inoculation.
Background
Carrion's disease is an infectious disease; endemic in
some regions of Peru, Colombia and Ecuador [1]. The eti-
ologic agent is Bartonella bacilliformis. In endemic areas,
the incidence of infection has been estimated at 12.7/100
person-years [2]. Carrion's disease is present in the
interandean valleys located between 500 and 3200 m
above sea level [3,4], where ecological conditions are
favorable for sand flies of the genus Lutzomyia, some spe-
cies of which transmit the disease [5]. No reservoirs other
than humans have been implicated in endemic areas[6-9].
There is limited information on the immunologic
response to Bartonella infection but it is widely known
that antibodies are detectable in convalescent patients
with long-term protective immunity [10-12]. The pres-
ence of chronic asymptomatic carriers in endemic areas
and the appearance of the chronic phase contribute to the
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may not be completely effective in clearing Bartonella
infection.
The most studied immunological model related to Car-
rion's disease is B. henselae infection, which results in a
wide range of clinical conditions including Cat Scratch
Disease (CSD) [13-15]. There is no good animal model
for B. bacilliformis infection [16]. Sensitized rabbits with
viable B. bacilliformis and increased their susceptibility to
lethality of subsequently administered Bartonella metabo-
lites. The objective of this research was to produce experi-




A single B. bacilliformis strain (ATCC#35685) and a
recently isolated strain from an acute phase patient
(IMTAVH#00032) was used in this study. B. bacilliformis
stocks were grown on 10% sheep blood Columbia Agar
flasks at 29°C. Bacteria were harvested in a laminar flow
hood, scraping colonies off the agar surface into brain
heart infusion (BHI) broth media. The cells were collected
by centrifugation and suspended in phosphate-buffered
saline solution (PBS). Colony-forming units (CFU) of
harvested Bartonella cultures were estimated using the Mc
Farland turbidity scale (0.5 mL of tube 0.5 of Mc Farland
scale ~1.5 × 108 CFU/mL).
Inoculations
B. bacilliformis was prepared as described above, and
thawed on ice prior to inoculation. Forty six BALB/c mice
(10–12 weeks old) were anaesthetized with ketamine and
administered live B. bacilliformis by the routes indicated as
described below. Additionally, forty six BALB/c control
mice were inoculated with sterile saline.
For intraperitoneal (i.p.), intradermal (i.d.) and subcuta-
neous (s.c.) immunization, mice were dosed with vol-
umes of 200 – 500 μL containing around 1.5, 3, or 4.5 ×
108 CFU of B. bacilliformis administered using a tuberculin
syringe and needle. For oral immunizations, mice were
dosed by using a 22-gauge gavages (force feeding) needle
attached to a 1 mL syringe. For intranasal (i.n.) immuni-
zations, mice were dosed with volumes of 10–50 μL con-
taining around 1.5 × 108 CFU of B. bacilliformis
administered into the nostrils using a micropipette fitted
with a 200 μL tip. Following immunizations, mice were
observed daily for signs of illness.
Animals were sacrificed at different times up to day 60
post-infection. Sections of formalin-fixed liver, spleen,
lung, kidney, brain, and lymph node tissue were stained
with hematoxylin and eosin.
Detection of B. bacilliformis in vivo
From all mice, bacterial loads in liver, spleen, lung, kid-
ney, brain and lymph nodes were determined by plating
of 10-fold serial dilutions of organ homogenates on
Columbia sheep blood agar. In addition, quantitative cul-
tures of blood specimens were performed at the time of
necropsy. Before samples were plated on Columbia agar,
erythrocytes were lysed either by freezing and thawing or
by vigorous mixing with distilled water. All cultures were
incubated at 27°C for at least 4 weeks before being
recorded as negative for growth.
Additionally, 4 i.d. immunized mice were subjected to
intradermal skin testing with B. bacilliformis (using the
harvested ATCC#35685 strain in 2 mice and the harvested
IMTAVH#00032 strain in the other 2), to monitor delayed
swelling reactions as an indication of specific immune
induction. The mice were boosted i.d. with 3 × 108 CFU
on day 50 after primary i.d. inoculation. One week after
the boost, each mouse was challenged in the right dorsal
skin with the same number of bacteria. The injection site
was monitored at 24, 48, and 72 hours for swelling
responses and compared to the control skin as an external
negative control. Swelling was determined from three
readings using a caliper.
Results
Eleven immunizations were done using different doses of
B. bacilliformis at different incubation periods (Table 1).
Spleen, liver, brain, and lymph nodes cultures did not
show cultivable organisms within the first 6 hours, 24
hours, and 7–14 days of infection. No organisms could be
recovered from blood or skin. Kidneys and lungs
remained sterile throughout this experiment. Subsequent
experiments with inoculate ranging from 1.5, 3, or 4.5 ×
108 CFU yielded similar results.
One animal showed histopathological alterations, 24
hours after i.p. inoculation of 1.5 × 108 viable B. bacilli-
formis. Many abscesses were found in the liver of this
mouse. Bacterial cultures were negative. Control mice
were negative.
No other organs showed abscess at any time. No granulo-
matous lesions were found in hematoxylin and eosin
stained liver sections.
Mice previously inoculated with live B. bacilliformis
showed no change in the site of a second inoculation
(dorsal skin).
Discussion
We have performed different mouse inoculation experi-
ments with varying numbers of B. bacilliformis. No bacte-Page 2 of 4
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Columbia Blood agar has been used to isolate B. bacilli-
formis in the clinical practice and is the medium for grow-
ing our bacteria in experimental conditions. In our study
the isolation of bacteria was not successful even when
using high inocula. Factors involved in host specificity
and ligand-receptor affinity can be involved in failure to
reproduce infection by many Bartonella species in BALB/c
mice [17]. Thin blood films were negative in our experi-
ments; thus, there was no bacteremia in BALB/c mice at
any time or by any inoculation route.
Intradermal and subcutaneous immunizations are the
experimental routes of infection most similar to natural
human infection, which is due to inoculation by the Lut-
zomyia bite. Our first experiments using the intradermal
route do not show histopathological lesions in skin nor
systemic infection even using higher inocula. Previously
immunized mice with harvested ATCC#35685 strain have
not shown any delayed-type hypersensitivity when they
were exposed to the same strain 50 days later.
A recently isolated (supposedly actively pathogenic) strain
from an acute phase patient was incapable of eliciting an
intradermal immune response. Boosters after 50 days
have not been useful to induce a cellular immune
response using harvested bacteria. Karem et al [14]
showed that two inoculations of B. henselae were enough
to show a cellular immune response in BALB/c mice.
Many boosters with B. bacilliformis may be necessary to
induce a cellular response.
We have found only one animal with liver abscesses 24
hours post-inoculation. The sterile saline inoculated (con-
trol) mouse showed similar liver abscesses, probably
attributed to a disease different to Bartonella.
Conclusion
The results of our experiments show that B. bacilliformis
didn't produce macro and microscopic organ lesions or
disease in BALB/c mice, using different inoculation routes,
and that bacteremia was absent after one to 15 days after
inoculation.
Intradermal re-inoculation of harvested B. bacilliformis
didn't elicit delayed-type hypersensitivity in BALB/c mice
even after a booster dose at 50 days of the primary inocu-
lation.
BALB/c mice are not useful as models for the human B.
bacilliformis infection, but exploration of their apparent
resistance to infection may yield important immunologi-
cal insights. New experiments to detect cytokine, immu-
noglobulin and cellular responses are necessary to
develop these explorations.
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Table 1: Experiments attempting infection of BALB/c mice with viable Bartonella bacilliformis
Exp Route No. of Micea CFUb Time to sacrifice Results of H/E stain
1 i.p. 03 1.5 × 108 7 days organs normal
2 i.p. 05 1.5 × 108 6, 24 hs & 14 days organs normal
3 i.p. 05 1.5 × 108 6, 24 hs & 14 days organs normal
4 s.c. 03 4.5 × 108 24 hs skin normal
5 s.c. 02 4.5 × 108 30 days skin normal
6 s.c. 07 1.5 × 108 2, 6 & 8 hs skin normal
7 Oral 03 1.5 × 108 24 hs organs normal
8 Oral 05 1.5 × 108 24 hs organs normal
9 i.n. 04 1.5 × 108 24 hs organs normal
10 i.d. 03 4.5 × 108 7 days skin normal
11 i.d. 02 4.5 × 108 30 days skin normal
12b i.d. 02 3 × 108 24, 48 & 72 hs No skin changes
13c i.d. 02 3 × 108 24, 48 & 72 hs No skin changes
aForty six control mice inoculated with sterile saline
bpreviously inoculated with viable ATCC#35685
cpreviously inoculated with viable, recently isolated B. bacilliformis from an acute phase patientPage 3 of 4
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